Cipla Ltd
NSE: CIPLA BSE: 500087
₹1300
(-2.17)%
Mon, 02 Feb 2026, 05:21 am
Market Cap1069.45B
PE Ratio23.11
Dividend0.98
Health Technology
Pharmaceuticals: Other
24.5Kcipla ltd History
1935
- Incorporated at Mumbai.
1979
- Acquired plot of land from MIDC at Patalganga in Kulaba district, Maharashtra, 55 kms from Mumbai.
- Issued 18,773 bonus equity shares in 1:1 proportion.
1984
- Changed name from The Chemical Industrial & Pharmaceutical Laboratories Ltd. to present name effective July 20.
1985
- Issued 37,546 bonus equity shares in 1:1 proportion in January 1986.
1986
- Obtained consent for 3,00,000 15% secured non-convertible redeemable debentures of Rs 100 each (Rs 300 lakhs) by private placement; fully subscribed by public financial institutions; redeemable at 5% premium in 1993-94.
1987
- Launched Asthalin, Beclate Rotahalers/Rotacaps, Presolar capsules, Restyl tablets, Theo-Asthalin SR tablets, Bromolin dry syrup and capsules, Dilgard tablets, Ibugesic plus suspension.
- Issued 75,092 bonus equity shares in 1:1 proportion.
1989
- Introduced Ciplox tablets and infusion, Cefadur capsules and syrup, Ulcimax tablets, Theoped syrup.
- PROTEC division sales exceeded Rs 5.50 crores.
1990
- Launched products: Aerocort inhaler, Norflox eye/ear drops, Pirox Gel, Cofenac, Kinetal 400, Novaclox Ped, Terfed, Depryl, Asthalin Respirator Solution.
- Spent Rs 4.22 crores on R&D and Rs 8.09 crores on modernisation and expansion.
1991
- Launched products: Lomac, Cromal inhaler, Ciplox eye drops, Etosid injection, Proflox, Vasopril.
- Developed felodipine, selegiline, cetirizine HCl, nimodipine, oxfendazole, oribendazole; advanced work on AZT.
- Offered 6,000 equity shares at par as rights to preference shareholders in 1:1 proportion; 5,216 shares taken up.
1992
- Introduced products: Zidovir, Cipril, Optipres, Felogard, Nodine.
- Redeemed 6,000 preference shares.
- Issued 1,55,395 bonus equity shares in 1:1 proportion.
1994
- Introduced products: Beclate Aquanase, Cytoplatin, Forcan, Imusporin, Kelfer, Lanzol, Nuzac, Odirox, Qinarsol.
- Subdivided equity shares; issued shares in 1:5 proportion.
- Commissioned manufacturing unit at Kurkumbh; started second phase expansion.
1995
- Declared lock-out at Vikhroli Unit due to indiscipline.
- Launched products: Acivir, Anlopres, Anlopres AT, Budecort 200, Budenase AQ, Cronal, Cytonid, Norflox, Optipes S, Profenac, Terfed D, Trivedon 20.
- Manufactured new chemical entity candocuronium iodide and bulk drugs: Acyclovir, Amlodipine besylate, Febantel, Flutamide, Fluticasone dipropionate, ZENPROLIDE acetate.
- Issued 13,43,383 rights equity shares at premium Rs. 60.
1996
- Launched products: Azee (azithromycin), Budecort rotacaps, Cipril H, Ciplox TZ, Entosec, Fincar, Metolar, Zoflut cream.
1997
- Launched products: Alerid-D, Amlopres L, Apuatears, Azee 1000, Budecort Respules, Dilgard XL, Glumet, Glygard, Ipranase AQ, Ocutim, Osteifos 10, Prolyte Fizz, Pylokit, Risnia, Stavir, Synclar 250, Theoday, Zoflut Lotion.
- Developed bulk drugs: budesonide, carvedilol, ebastine, formoterol fumarate, meloxicam, moclobemide, mometasone furoate, pantoprazole sodium sesquihydrate, sildenafil citrate.
- Commissioned form-fill-seal equipment for sterile formulations; set up capacities for effervescent tablets, soft gel capsules, injectables; incurred Rs 22.73 crores capital expenditure.
- Finalised marketing joint venture with Genpharm.
- Entered sourcing arrangement with Geneva Pharmaceuticals for generic drugs.
1998
- Proposed share buyback and new Article 64A in Articles of Association.
1999
- Entered strategic partnership with Ranbaxy to jointly market Carvedilol and Cefpodoxime Proxetil.
- Forged strategic alliance with UK-based Neolab for generic drugs.
- Worked on ANDAs with international generics firms for flutamide and felodipine.
2000
- Expanded partnership with Ranbaxy Laboratories by adding one more drug to co-marketing arrangement.
2001
- Tied up with Zenith Goldline and United Research Labs for Flutamide and Felodipine in US and Europe.
- Dispatched first free consignment of anti-AIDS drug Nevirapine to Indian Government.
2002
- Reduced prices of anti-HIV medicines including Stavir, Lamivir, Nevimune, Dinex, Indivan, Triomune, Efavir, and Duovir.
- Revoked interim dividend of Rs 5 per share for FY 2001-02.
- Included in WHO list of HIV-related products.
- YK Hamied received lifetime contribution award from Union chemicals minister.
- Resigned from Indian Pharmaceutical Alliance over Patents Bill.
2003
- Applied for ANDA with US regulators for post-menopausal drug.
- Received NPPA notices for overcharging products.
- Completed research studies on three Anti-HIV drugs.
- Registered Stavudine, Nevirapine, and other anti-AIDS products in South Africa.
2004
- Signed long-term agreement with Morton Grove Pharmaceuticals for US market launch.
- Forged alliance with Avesthagen.
- Joined Vatican global initiative CUMVIVIUM.
- Joined hands with Pentech Pharma.
- Patented Triomune in South Africa.
- Introduced Duova for chronic obstructive pulmonary disease.
- Launched arthritis treatment with Cymbiotics Inc.
2005
- Set up state-of-the-art formulations facility at Baddi, Himachal Pradesh.
- Introduced new drug for arthritis.
- Planned deal with Akorn Inc for anti-infective drug.
- Planned production of generic bird-flu drug.
- Planned tie-up with Roche.
2006
- Received Scrip Award for Best Company in an Emerging Market.
- Set up subsidiary in Dubai.
- Tied up with Ivax for US market.
- Received tentative US FDA approval for AIDS drugs.
- Received Pharma Excellence Award for Sustained Growth.
- Issued bonus shares in 3:2 ratio.
2007
- Unveiled anti-malaria global initiative.
- Set up state-of-the-art formulations facility at Sikkim.
- Received Forbes Asia's Best Under A Billion award.
- Drug included in US anti-AIDS initiative.
- Launched emergency contraception tablet.
- Launched estradiol transdermal spray in India.
- Launched cut-price zanamivir in India.
- Received International Trade Awards 2006 for outstanding exporter.
2008
- Appointed Mr. Pankaj Patel as Director effective March 05.
- Launched Roche's generic version of anti-infection drug.
2009
- Won Erlotinib case against Roche.
- Received Pharmaceuticals Export Promotion Council Awards.
- Launched drug to treat Swine flu virus.
- Won patent fight against Gilead Sciences.
2010
- Acquired Meditab Specialities Pvt. Ltd. for Rs. 133.35 crores.
- Cipla Medpro signed deal with Biomab (Desano Pharma).
- Sold marketing rights of i-Pill to Piramal Healthcare for Rs 95 crore.
- Tied up with Stempeutics Research.
- Launched generic Pirfenidone for Idiopathic Pulmonary Fibrosis.
2011
- Launched 24-hour helpline for Cancer Palliative Care Centre.
2012
- Agreed to acquire 51% stake in Cipla Medpro for $220 million.
- Bagged tentative approval for HIV treatment tablets.
- Announced price reduction on anti-cancer drugs Erlotinib, Docetaxel, and Capecitabine.
- Bagged Platinum award for export of pharmaceuticals.
2013
- Announced offer to Medpro shareholders for 100% acquisition.
- Launched first biosimilar of Etanercept in India.
2014
- Won USD 188.95 million Global Fund ARV Tender.
- Collaborated with MMV and Strides.
- Licensed rights for innovative product.
- Collaborated with S&D Pharma to enter Czech Republic and Slovakia.
- Collaborated with Hetero to launch biosimilar Darbepoetin alfa.
- Invested in Chase Pharmaceuticals for Alzheimer’s disease drug development.
- Shifted registered office to Cipla House, Lower Parel, Mumbai.
2015
- Entered agreement with Biopharma SPA for joint venture company in Algeria.
- Launched generic Sofosbuvir (Hepcvir).
- Inked agreement with Serum Institute of India to market Nasovac-S flu vaccine.
- Launched anti-ageing skin care product Cutisera.
- Launched generic hepatitis C tablets (Hepcvir-L).
2016
- Received CCI approval for investment by FIL Capital.
- Completed acquisition of generic businesses in US.
- Received USFDA approval for generic anti-depressant drug.
- Received EIR from US FDA for Indore facility.
- Received USFDA final approval for Hepatitis B treatment drug.
- Received final approval for generic Baraclude tablets.
2017
- Authorized Key Managerial Personnel to determine materiality of events/information.
- Launched Hepatitis B vaccine in India.
- Received approval for Lamivudine Tablets.
- Cipla USA signed licensing agreement with MEDRx.
- Received WHO approval to sell TB preventing drug in HIV patients.
- Launched Q-TIB globally.
- Launched Rectal Artesunate Suppositories for severe malaria in young children.
- Received final approval for generic Epzicom Tablets.
2018
- Teamed up with Roche Pharma to sell cancer therapy drugs in India.
- Partnered with Eli Lilly to market diabetes drug Basaglar in India.
- Received USFDA final approval for generic Valganciclovir Tablets 450mg.
- Bagged DMA Asia Echo Award (Silver) for Best Digital Destination and Leader Certificate in Pharma & Healthcare.
2019
- Planned launch of cinacalcet hydrochloride tablets in US market.
- Introduced Niveoli, India's first HFA inhaler for airway diseases.
- Received 18th ICSI National Award for Excellence in Corporate Governance.
2020
- Completed phase-3 clinical study of generic asthma drug.
- Inked licensing pact with Gilead Sciences for potential COVID-19 treatment drug.
- Launched generic remdesivir for coronavirus patients.
- Collaborated with Stempeutics to launch Stempeucel for CLI treatment in India.
- Launched antibody detection kit for COVID-19 in India.
- Conferred Golden Peacock Global Award for Excellence in Corporate Governance 2020.
2021
- Set up 30 MW solar plant in Maharashtra.
- Partnered with Alvotech to market biosimilars in Australia and New Zealand.
- Bagged National Energy Conservation Award 2021 in drug and pharmaceutical sector.
- Won Gold for Remdesivir in Covid Care Brand Category.
2022
- Launched leuprolide acetate injection depot (22.5mg).
- Received USFDA approval for generic Revlimid (Lenalidomide Capsules).
- Launched child-friendly 4-in-1 antiretroviral treatment for HIV with DNDi in South Africa.
- Scored highest among pharma companies in CRISIL Sustainability Rating 2022.
- Won Frost & Sullivan and TERI Sustainability 4.0 Award.
2023
- Acquired additional stake in GoApptiv Private Limited.
- Announced acquisition of South Africa-based Actor Pharma.
2024
- Acquired additional shares in Achira Labs Private Limited.
- Merged Cipla Technologies LLC, USA with Cipla USA Inc.
- Announced joint venture in the US with Kemwell Biopharma and Manipal Education & Medical Group for cell therapy products.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800